SkinBioTherapeutics plc (AIM:SBTX) (SBTX) said in a filing that the interim results for the six months ended 31 December 2025 will not be published by the AIM deadline and will be delayed until an independent Board investigation is complete, with trading in the group's ordinary shares expected to be suspended from 7.30am on 1 April 2026.
The Board appointed FRP Advisory on 20 February 2026 to carry out a forensic review into matters the company first outlined on 16 February 2026, and "whilst progress is being made, this forensic review is ongoing", the company said, adding it will therefore not be able to meet the 31 March 2026 announcement requirement under the AIM Rules.
The filing said the Group had cash of £2.44m at close of business on 19 March 2026 and that its businesses are trading on a "business as usual" basis, the company said.
The Board said it will update shareholders on the outcome of the forensic review and Board investigation as soon as possible, according to the filing.
